Semaglutide launch overview

Pharmaceutical ingredient prices shifted in 2025 – and mostly downward. The QYOBO API1000 Index, tracking the 1,000 most commonly traded APIs, shows that 55% of APIs declined in price between 2024 and 2025, with a median drop of 11%. Only 32% saw increases.

Price trends of selected substances within key segments based on QYOBO platform data:

OTC APIs: Prices mostly declined, with Simethicone (-29%) showing the largest decrease, while a few (e.g. Metamizole +13%, Menthol +14%) increased – reflecting typical price pressure in mature, highly competitive markets.
Biologic & peptide APIs: Prices mostly declined, while Semaglutide (+13%) stood out as the only GLP-1 with a price increase, supported by recent FDA approvals, anticipated generic launches, and expansion into new markets such as India, Brazil, Canada, and China, in contrast to sharp declines for Tirzepatide (-55%) and Liraglutide (-20%).
Intermediates: Prices declined, with particularly strong pressure in antibiotic supply chains – including 6-APA (-30%), levofloxacin carboxylic acid (-22%), and SMIA (-19%) – reflecting ongoing competitive dynamics and recent policy interventions such as India’s introduction of minimum import prices (MIP) for key antibiotic inputs to support domestic production.
Excipients: Prices showed a mixed trend, with several commonly used substances declining (e.g. Gelatin -13%, Sugar -11%), while others increased – including Lactose (+11%) and Acesulfame potassium (+19%).

Trusted market prices and AI-based forecasts across 10,000+ APIs, intermediates, key starting materials, and excipients – with granular filters including country-level insights – are exclusively available on the QYOBO platform.